![André J. Müller](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
André J. Müller
Directeur/Membre du Conseil chez
Anokion SA
Profil
André J.
Müller was the founder of Actelion Ltd. (1999) where he held the title of Vice Chairman in 2009.
Mr. Müller is also the founder of REFERENCE CAPITAL SA. Currently, he is a Director at Anokion SA. Previously, he held the position of Chairman at Addex Therapeutics Ltd. (2002-2014) and ABIONYX Pharma SA. He was also a Director at Synthes, Inc., Kanyos Bio, Inc., and Chief Financial Officer at Biogen, Inc. Mr. Müller received an MBA from INSEAD and an undergraduate degree from the University of Geneva.
Postes actifs de André J. Müller
| Sociétés | Poste | Début |
|---|---|---|
Anokion SA
 Anokion SA BiotechnologyHealth Technology Operates as a biotechnology company which develops therapies for antigen-specific immune tolerance | Directeur/Membre du Conseil | - |
Anciens postes connus de André J. Müller
| Sociétés | Poste | Fin |
|---|---|---|
| ADDEX THERAPEUTICS LTD | Président | 27/06/2014 |
| ACTELION | Fondateur | 01/04/2009 |
Kanyos Bio, Inc.
 Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for type 1 diabetes | Directeur/Membre du Conseil | - |
REFERENCE CAPITAL SA
 REFERENCE CAPITAL SA Investment ManagersFinance Genevest's portfolio of investments has reached maturity. The firm primarily oversees exit operations through trade sales and IPOs. Their past investments focused on sectors such as IT, communications, materials science, medical technology and life sciences, primarily in Europe and selectively in the US and Israel. The firm typically holds minority stakes in syndication with other investors, and generally does not sit on the board of their portfolio companies. | Fondateur | - |
Synthes, Inc.
 Synthes, Inc. Medical SpecialtiesHealth Technology Develops, produces & markets instruments, implants and biomaterials for surgical fixation, correction, regeneration of human skeleton & soft tissues | Directeur/Membre du Conseil | - |
Formation de André J. Müller
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
45
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Synthes, Inc.
Synthes, Inc. Medical SpecialtiesHealth Technology Develops, produces & markets instruments, implants and biomaterials for surgical fixation, correction, regeneration of human skeleton & soft tissues | Health Technology |
Actelion Ltd.
 Actelion Ltd. Pharmaceuticals: MajorHealth Technology Develops, produces and markets pharmaceutical drugs | Health Technology |
INSEAD
 INSEAD Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
REFERENCE CAPITAL SA
REFERENCE CAPITAL SA Investment ManagersFinance Genevest's portfolio of investments has reached maturity. The firm primarily oversees exit operations through trade sales and IPOs. Their past investments focused on sectors such as IT, communications, materials science, medical technology and life sciences, primarily in Europe and selectively in the US and Israel. The firm typically holds minority stakes in syndication with other investors, and generally does not sit on the board of their portfolio companies. | Finance |
Addex Therapeutics Ltd.
 Addex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops and commercializes drugs | Health Technology |
University of Geneva
 University of Geneva Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ABIONYX Pharma SA
 ABIONYX Pharma SA Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes novel HDL therapies for the treatment of cardiovascular and metabolic diseases | Health Technology |
Anokion SA
Anokion SA BiotechnologyHealth Technology Operates as a biotechnology company which develops therapies for antigen-specific immune tolerance | Health Technology |
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for type 1 diabetes | Health Technology |
